Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study

被引：0
|
作者：
Mustafayev, Khalis [1 ]
Guevara, Eduardo Yepez [1 ]
DiNardo, Courtney D. [2 ]
Jabbour, Elias [2 ]
Ghayas, Issa C. [2 ]
Ratan, Ravin [3 ]
Pemmaraju, Naveen [2 ]
Torres, Harrys A. [1 ,4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX USA
来源：
LEUKEMIA RESEARCH | 2024年 / 147卷
关键词：
Dasatinib; Imatinib; Ponatinib; Chronic myeloid leukemia; Viral hepatitis; HCV;
D O I：
10.1016/j.leukres.2024.107597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] VIROLOGIC EFFECT AND HEPATOTOXICITY OF BCR-ABL TYROSINE KINASE INHIBITORS IN CANCER PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: A PROSPECTIVE STUDY
    Mustafayev, Khalis
    Guevara, Eduardo Yepez
    DiNardo, Courtney
    Jabbour, Elias
    Ghayas, Issa
    Ratan, Ravin
    Pemmaraju, Naveen
    Torres, Harrys
    HEPATOLOGY, 2024, 80 : S391 - S392
  • [2] Adverse drug reactions reported with BCR/ABL1 tyrosine kinase inhibitors
    Tournaire, G.
    Despas, F.
    Rousseau, V.
    Montastruc, J. L.
    Bondon-Guitton, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 47 - 47
  • [3] Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors
    Haddad, Fadi G.
    Kantarjian, Hagop
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (01):
  • [4] The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors
    Jabbour, Elias J.
    Sasaki, Koji
    Haddad, Fadi G.
    Issa, Ghayas C.
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Jain, Nitin
    Yilmaz, Musa
    DiNardo, Courtney D.
    Patel, Keyur P.
    Kanagal-Shamanna, Rashmi
    Champlin, Richard
    Khouri, Issa F.
    Dellasala, Sara
    Pierce, Sherry A.
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (04) : 658 - 665
  • [5] BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
    Joseph Kauer
    Melanie Märklin
    Martin Pflügler
    Sebastian Hörner
    Clemens Hinterleitner
    Claudia Tandler
    Gundram Jung
    Helmut R. Salih
    Jonas S. Heitmann
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2759 - 2771
  • [6] BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
    Kauer, Joseph
    Maerklin, Melanie
    Pfluegler, Martin
    Hoerner, Sebastian
    Hinterleitner, Clemens
    Tandler, Claudia
    Jung, Gundram
    Salih, Helmut R.
    Heitmann, Jonas S.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (10) : 2759 - 2771
  • [7] A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line
    Airiau, Kelly
    Turcq, Beatrice
    Mahon, Francois-Xavier
    Belloc, Francis
    LEUKEMIA RESEARCH, 2017, 61 : 44 - 52
  • [8] ANALYSIS OF THE REACTIVATION OF HEPATITIS B VIRUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN TREATMENT WITH INHIBITORS OF THE TYROSINE KINASE BCR-ABL
    Sanz Ruperez, A.
    Ruiz Gomez, F.
    Garcia Gutierrez, V
    Herrera Puente, P.
    Calbacho Robles, M.
    Velazquez Kennedy, K.
    Geijo Roman, Martinez C.
    Lopez Jimenez, J.
    HAEMATOLOGICA, 2017, 102 : 279 - 279
  • [9] Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Eide, Christopher A.
    Bottomly, Daniel
    Savage, Samantha L.
    White, Libbey
    Wilmot, Beth
    Schultz, Anna M. Reister
    Uchida, Kimberly A.
    Agarwal, Anupriya
    Traer, Elie
    Beppu, Lan
    Sala-Torra, Olga
    Radich, Jerald P.
    Eickelberg, Garrett
    Press, Richard D.
    Loriaux, Marc M.
    Tantravahi, Srinivas K.
    Pomicter, Anthony D.
    Zabriskie, Matthew S.
    Deininger, Michael W.
    O'Hare, Thomas
    Tyner, Jeffrey W.
    McWeeney, Shannon K.
    Tognon, Cristina E.
    Druker, Brian J.
    BLOOD, 2016, 128 (22)
  • [10] Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress
    Kantarjian, Hagop M. M.
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (09) : 1350 - 1353
12345